TriangleNCT01816984 · OUTCOME
Progression Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 4 years and 3 months
What was measured
Progression free survival is defined as the time from study initiation to first evidence of progression of disease.
Groups in this outcome
Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)
Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter. All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. PI3K inhibitor BKM120: Given PO cetuximab: Given IV
| Group | Source count |
|---|---|
| Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days) | 12 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days) | 2 | Not reported | 1.7 | 5 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.7
- upper Limit
- 5
- value
- 2
- denoms
- counts
- group Id
- OG000
- value
- 12
- units
- Participants
- description
- Progression free survival is defined as the time from study initiation to first evidence of progression of disease.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter. All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. PI3K inhibitor BKM120: Given PO cetuximab: Given IV
- id
- OG000
- title
- Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- 4 years and 3 months
- title
- Progression Free Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice